WO2004035033A3 - Combinaison chimiotherapeutique de clofarabine et de camptothecine - Google Patents

Combinaison chimiotherapeutique de clofarabine et de camptothecine Download PDF

Info

Publication number
WO2004035033A3
WO2004035033A3 PCT/US2003/032515 US0332515W WO2004035033A3 WO 2004035033 A3 WO2004035033 A3 WO 2004035033A3 US 0332515 W US0332515 W US 0332515W WO 2004035033 A3 WO2004035033 A3 WO 2004035033A3
Authority
WO
WIPO (PCT)
Prior art keywords
clofarabine
camptothecin
chemotherapy combination
combination
chemotherapy
Prior art date
Application number
PCT/US2003/032515
Other languages
English (en)
Other versions
WO2004035033A2 (fr
Inventor
Sean T Wilson
Steven D Weitman
Katherine Stephenson
Original Assignee
Ilex Products Inc
Sean T Wilson
Steven D Weitman
Katherine Stephenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilex Products Inc, Sean T Wilson, Steven D Weitman, Katherine Stephenson filed Critical Ilex Products Inc
Priority to AU2003301245A priority Critical patent/AU2003301245A1/en
Publication of WO2004035033A2 publication Critical patent/WO2004035033A2/fr
Publication of WO2004035033A3 publication Critical patent/WO2004035033A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une combinaison de clorafabine et d'un analogue de camptothécine utilisée dans le traitement des cancers.
PCT/US2003/032515 2002-10-16 2003-10-14 Combinaison chimiotherapeutique de clofarabine et de camptothecine WO2004035033A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003301245A AU2003301245A1 (en) 2002-10-16 2003-10-14 Clofarabine and camptothecin chemotherapy combination

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41906502P 2002-10-16 2002-10-16
US60/419.065 2002-10-16
US45947603P 2003-04-01 2003-04-01
US60/459.476 2003-04-01

Publications (2)

Publication Number Publication Date
WO2004035033A2 WO2004035033A2 (fr) 2004-04-29
WO2004035033A3 true WO2004035033A3 (fr) 2004-07-22

Family

ID=32110211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032515 WO2004035033A2 (fr) 2002-10-16 2003-10-14 Combinaison chimiotherapeutique de clofarabine et de camptothecine

Country Status (2)

Country Link
AU (1) AU2003301245A1 (fr)
WO (1) WO2004035033A2 (fr)

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BERAN M ET AL: "Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside (ara-C) in previously untreated patients with high-risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML)", BLOOD, vol. 90, no. 10 SUPPL. 1 PART 1, 15 November 1997 (1997-11-15), 39th Annual Meeting of the American Society of Hematology;San Diego, California, USA; December 5-9, 1997, pages 583A, XP009027996, ISSN: 0006-4971 *
CERSOSIMO R J: "IRINOTECAN: A NEW ANTINEOPLASTIC AGENT FOR THE MANAGEMENT OF COLORECTAL CANCER", ANNALS OF PHARMACOTHERAPY, XX, XX, vol. 32, no. 12, December 1998 (1998-12-01), pages 1324 - 1333, XP008018483, ISSN: 1060-0280 *
KANTARJIAN HAGOP M ET AL: "Phase I and pharmacology study of clofarabine (2-Cl-2'-F-deoxy-9-D-arabino-furanosyladenine) in solid and hematologic cancers", BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), 43rd Annual Meeting of the American Society of Hematology, Part 2;Orlando, Florida, USA; December 07-11, 2001, pages 214b, XP009027998, ISSN: 0006-4971 *
KEHRER D F S ET AL: "MODULATION OF CAMPTOTHECIN ANALOGS IN THE TREATMENT OF CANCER: A REVIEW", ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, GB, vol. 2, no. 12, February 2001 (2001-02-01), pages 89 - 105, XP008002866, ISSN: 0959-4973 *
KOLLMANNSBERGER C ET AL: "TOPOTECAN-A NOVEL TOPOISOMERASE I INHIBITOR: PHARMACOLOGY AND CLINICAL EXPERIENCE", ONCOLOGY, S. KARGER AG, BASEL, CH, vol. 1, no. 56, 1999, pages 1 - 12, XP001064576, ISSN: 0030-2414 *
RIZZIERI D A ET AL: "Phase I trial of continuously infused gemcitabine with CPT-11 for refractory hematologic malignancies", BLOOD, vol. 96, no. 11 Part 2, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 216b, XP009027999, ISSN: 0006-4971 *
WEITMAN STEVEN D ET AL: "Antitumor effect of combination treatment with clofarabine and CPT-11 in the HT-29 human colorectal tumor xenograft model.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 44, July 2003 (2003-07-01), 94th Annual Meeting of the American Association for Cancer Research;Washington, DC, USA; July 11-14, 2003, July 2003, pages 161, XP001180279, ISSN: 0197-016X *

Also Published As

Publication number Publication date
WO2004035033A2 (fr) 2004-04-29
AU2003301245A1 (en) 2004-05-04
AU2003301245A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2004045464A3 (fr) Dispositifs medicaux
ZA200302039B (en) Paclitaxel-based antitumor formulation.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
LUC00065I1 (fr)
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
MX2007006830A (es) Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
WO2005085188A3 (fr) Composes et procedes pour la therapie antitumorale
WO2003099217A3 (fr) Methodes de traitement d'infections bacteriennes et de maladies associees
ZA200604874B (en) Pharmaceutical compositions
AU2003290592A1 (en) Antitumor benzoylsulfonamides
WO2004031352A3 (fr) Variants d'interferons presentant des proprietes ameliorees
WO2004041158A3 (fr) Compositions de rifalazil et regimes therapeutiques
WO2005000208A3 (fr) Therapie combinee pour le traitement des neoplasmes
TW200510398A (en) Novel compounds
WO2004108062A3 (fr) Prophylaxie et/ou therapie de l'hypertonie portale
UA91694C2 (ru) Применение эмодепсида и pf1022a для предотвращения вертикальных эндопаразитарных инфекций
WO2004092208A3 (fr) Proteines associees au sras
WO2005000204A3 (fr) Traitement du cancer du pancreas
WO2005010165A3 (fr) Alpha-fetoproteine humaine non-glycosylee, procedes de production et utilisations de celle-ci
WO2005081972A3 (fr) Inhibiteurs de phosphatase antitumoraux a base de maleiimide
AU2003223538A1 (en) Methods for the treatment of cancer
WO2004105696A3 (fr) Therapie combinatoire pour le traitement des neoplasmes
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
AU2003286840A1 (en) Methods and compositions for the diagnosis of neuroendocrine lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP